Search

Type

Audience

Category

Issue

Last updated

Please note: using the search filters may not provide accurate search results for records prior to November 2021. When searching for older records, please ensure that you use the include archive checkbox.

Displaying 1 - 2 of 2 items.

Health alert or recall Casirivimab and Imdevimab – High Risk of Treatment Failure Due to Circulation of SARS-CoV-2 Omicron Variant
… Last updated 2022-01-07 Summary Product Casirivimab and Imdevimab Issue Health products - New safety information … below Audience Health professionals Affected products Casirivimab and imdevimab concentrate for infusion is …
AlertHealth professional risk communication | 2022-01-07
Health alert or recall Authorization of Casirivimab and Imdevimab with English-only Labels for Use in Relation to the COVID-19 Pandemic
… room (ER) physicians. Key messages On June 9, 2021, casirivimab and imdevimab, two monoclonal antibodies, were authorized for use … and Advertising of Drugs for Use in Relation to COVID-19 . Casirivimab and imdevimab, to be administered together, are …
AlertHealth professional risk communication | 2021-07-30
Report a problem or mistake on this page
What was wrong?

You will not receive a reply. Telephone numbers and e-mail addresses will be removed.

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.